Article
Endocrinology & Metabolism
Laris Achlaug, Lina Somri-Gannam, Shilhav Meisel-Sharon, Rive Sarfstein, Manisha Dixit, Shoshana Yakar, Mordechai Hallak, Zvi Laron, Haim Werner, Ilan Bruchim
Summary: This study evaluated the expression of ZYG11A in EOC patients and found reduced ZYG11A expression in high grade tumors, suggesting a potential tumor suppressor role. The study also identified an inverse correlation between ZYG11A and p53 levels in individual tumors. Further exploration of ZYG11A as a novel biomarker in EOC is warranted based on these findings.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Eric B. Nonnecke, Patricia A. Castillo, Malin E. Johansson, Edward J. Hollox, Bo Shen, Bo Lonnerdal, Charles L. Bevins
Summary: This study investigates the differences between ITLN2 and ITLN1 in terms of their structure and expression characteristics. It reveals that ITLN2 is a highly abundant Paneth cell-specific product in the small intestine, and its expression is downregulated in Crohn's disease. ITLN2 mRNA expression is undetectable in control colon tissue, but metaplastic Paneth cells express ITLN2 in both ulcerative colitis and colonic Crohn's disease.
Article
Oncology
Zhengwei Gui, Yao Tian, Shiyang Liu, Tianyao Yu, Chenguang Liu, Lin Zhang
Summary: This study investigated the expression of Centromere protein L (CENPL) in breast cancer and its relationship with patient prognosis. High CENPL expression was found to be associated with the cell cycle, nuclear division, organelle fission, and chromosome segregation in breast cancer. Furthermore, high CENPL expression was correlated with immune cell infiltration and ICP gene expression. Inhibition of CENPL reduced the proliferation and migration ability of breast cancer cells. Therefore, CENPL may function as an oncogene in breast cancer and serve as a predictor of immunotherapy efficacy.
FRONTIERS IN ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Elissa D. Vazquez, Xiangyi Fang, Lauren A. Levesque, Mike Huynh, Citlali Venegas, Nhien Lu, Nicole Salazar
Summary: Racial disparities in chemokine receptor expression in breast tumors among Black, Asian, and White patients were found, which can contribute to improved treatment strategies and decreased racial disparities in breast cancer burden.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Samuel J. Rodgers, Lisa M. Ooms, Christina A. Mitchell
Summary: Wnt/β-catenin signaling is hyperactivated in many human cancers, including 50% of breast cancers. Repurposing the FDA-approved drug pyrvinium, which suppresses Wnt signaling, may be a more efficient method to target this pathway. We demonstrate that breast cancer cells with high expression of the oncogene INPP4B are selectively sensitive to pyrvinium treatment, suggesting its potential as a therapeutic strategy for breast cancers with high INPP4B expression.
Article
Oncology
Kevin Yijun Fan, Rania Chehade, Maleeha Qazi, Veronika Moravan, Sharon Nofech-Mozes, Katarzyna J. Jerzak
Summary: We evaluated the expression of androgen receptor (AR) in breast cancer brain metastases (BrM). AR was expressed in the majority of BrM and its expression varied across breast cancer subtypes. AR-positive status did not have a significant impact on overall survival, brain-specific progression-free survival, or time from breast cancer diagnosis to BrM diagnosis. AR represents a potential therapeutic target in breast cancer BrM.
Article
Nutrition & Dietetics
Ronald B. Brown, Philip Bigelow, Joel A. Dubin, John G. Mielke
Summary: Research shows that high dietary phosphorus intake is associated with increased mortality, phosphate toxicity, and tumorigenesis. A case-control study found that daily intake of >1800 mg of phosphorus was associated with a 2.3-fold increased risk of breast cancer. Further investigations are warranted to confirm these findings and explore the potential benefits of a low-phosphate diet for breast cancer patients.
Article
Neurosciences
Jack F. Webster, Rozan Vroman, Sanne Beerens, Shuzo Sakata, Christian Wozny
Summary: The lateral habenula (LHb) is pathologically hyperactive in depression and inhibiting it has been shown to have antidepressant effects. While there are proposed locally targeting inhibitory interneuron populations within the LHb, specific molecular markers for studying these neurons are sparse. Recent research using neuron-derived neurotrophic factor (NDNF) as a marker for neocortical neurogliaform cells found that while NDNF was selectively expressed in the neocortex, it was not confined to a specific subpopulation within the LHb, indicating the need for validation of molecular markers for diverse populations of neurons in different brain structures.
EUROPEAN JOURNAL OF NEUROSCIENCE
(2021)
Article
Oncology
Orla T. T. Cox, Neil O'Sullivan, Emilie Tresse, Stephanie Ward, Niamh Buckley, Rosemary O'Connor
Summary: The PDZ-LIM domain-containing protein 2 (PDLIM2) is found to be highly expressed in Triple Negative Breast Cancer (TNBC) and is associated with infiltrating M2 macrophages, suggesting its role in tumor progression.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Patricia Camara-Sanchez, Zamira Diaz-Riascos, Natalia Garcia-Aranda, Petra Gener, Joaquin Seras-Franzoso, Micaela Giani-Alonso, Miriam Royo, Esther Vazquez, Simo Schwartz Jr, Ibane Abasolo
Summary: This study aimed to find potential drugs targeting cancer stem cells (CSCs) in triple negative breast cancer (TNBC). The results showed that 8-quinolinol (8Q) and niclosamide (NCS) exhibited significant anti-CSC activity in vitro and in vivo, and had a synergistic effect with PTX in inhibiting the proliferation of cancer cells and viability of CSCs. Additionally, the combination of NCS and PTX reduced tumor growth and metastasis. These findings provide new insights for the development of more effective treatments for TNBC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Takahiro Ichikawa, Masahiro Shibata, Takahiro Inaishi, Ikumi Soeda, Mitsuro Kanda, Masamichi Hayashi, Yuko Takano, Dai Takeuchi, Nobuyuki Tsunoda, Yasuhiro Kodera, Toyone Kikumori
Summary: This study indicates that SYT13 is highly expressed in ER-positive breast cancer cells and clinical specimens, showing a positive association with the ER signaling pathways.
Article
Oncology
Clemens Hinterleitner, Yanjun Zhou, Claudia Tandler, Jonas S. Heitmann, Korbinian N. Kropp, Martina Hinterleitner, Andre Koch, Andreas D. Hartkopf, Lars Zender, Helmut R. Salih, Stefanie Maurer
Summary: The study shows that TACI expression on platelets is significantly increased in breast cancer patients and correlates with tumor progression, making it a potential prognostic marker for breast cancer.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Rongrong Wu, Arya Mariam Roy, Yoshihisa Tokumaru, Shipra Gandhi, Mariko Asaoka, Masanori Oshi, Li Yan, Takashi Ishikawa, Kazuaki Takabe
Summary: Tumor dormancy is an important mechanism for late breast cancer recurrence. This study investigates the clinical relevance of NR2F1 expression, a known biomarker for dormancy. The results show that high NR2F1 expression in breast cancer is associated with enriched metastasis and stem cell-related pathways, as well as suppressed cell proliferation. Furthermore, NR2F1 is predominantly expressed in cancer-associated fibroblasts, rather than in cancer cells.
Article
Oncology
Kang Wang, Lun Li, Sebastia Franch-Exposito, Xin Le, Jun Tang, Qing Li, Qianxue Wu, Laia Bassaganyas, Jordi Camps, Xiang Zhang, Hongyuan Li, Theodoros Foukakis, Tingxiu Xiang, Jiong Wu, Guosheng Ren
Summary: High-grade ER(+)HER2(-) breast cancer shows distinct clinical and molecular characteristics compared to low-grade tumors, with a worse prognosis, suggesting the need for clinical trials to test novel therapies.
MOLECULAR ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Minmin Fan, Jian Gao, Lin Zhou, Wenwen Xue, Yixuan Wang, Jingwei Chen, Wuhao Li, Ying Yu, Bo Liu, Yan Shen, Qiang Xu
Summary: The expression of SERCA2 in triple negative breast cancer (TNBC) patients is closely related to disease progression, and it also promotes the growth, migration and chemoresistance of breast cancer cells. Through experiments, it is proven that SERCA2 can interact with LC3B, induce cell autophagy, and increase the tolerance of breast cancer cells to drugs. In addition, it is found that targeting SERCA2 can increase cell autophagy and induce cell death, achieving the therapeutic effect of treating breast cancer.
ACTA PHARMACEUTICA SINICA B
(2022)